Sunil D. Pandit, Ph.D is currently a Senior Manager in the Next-generation diagnostics business at Siemens Healthcare Diagnostics and has 10+ yrs of experience in diagnostics industry. Dr. Pandit is responsible for research and early development activities, including efforts for novel assay and technology development for companion diagnostics and their transfer to IVD development or as Laboratory Developed Tests (LDTs). Previously, he has held positions of increasing responsibility in public and private sector at National Cancer Institute (NCI), National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), and as a CLIA lab Director at Vircolabs, Inc (JNJ). Dr. Pandit has extensive experience in the fields of genomics, molecular biology, molecular imaging and cancer biology. He received his Ph.D. in Biochemistry and Molecular Biology from State University of New York (SUNY) at Stony Brook, New York, and completed his postdoctoral research in Human genetics and genomics from the Washington University School of Medicine, St. Louis.
An Automated Platform for Enrichment, Detection, and Enumeration of Circulating Tumor Cells (CTCs): Potential Application as a Liquid Biopsy for Development of Companion Diagnostic Tests
Monday, 27 October 2014 at 10:45
Add to Calendar ▼2014-10-27 10:45:002014-10-27 11:45:00Europe/LondonAn Automated Platform for Enrichment, Detection, and Enumeration of Circulating Tumor Cells (CTCs): Potential Application as a Liquid Biopsy for Development of Companion Diagnostic TestsSELECTBIOenquiries@selectbiosciences.com
Siemens Healthcare Diagnostics is a global diagnostics company with a CAP accredited CLIA laboratory, the Siemens Clinical Laboratory (SCL) based in Berkeley, California. SCL provides test development and clinical trials testing expertize for pharmaceutical companion diagnostics needs, including enabling access to cutting-edge diagnostic technologies. In this presentation, the speaker will describe a novel Siemens circulating tumor cell (CTC) platform technology that may be used for companion diagnostic assay development at SCL. The ability to isolate and characterize rare circulating tumor cells (CTCs) has the promise of enhancing diagnosis, prognosis, resistance monitoring, and our understanding of cancer progression. Siemens has developed a platform for automated enrichment and characterization of CTCs in whole blood samples. The CTC system utilizes an automated liquid sample handling system to process blood samples and immunostain cellular proteins. CTC enrichment and staining is followed by imaging techniques to scan and analyse fluorescently-labelled cells. This technology is non-commercial and for Research Use Only (RUO).
Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion DiagnosticsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-10-27 10:45:002014-10-27 11:45:00Europe/LondonAn Automated Platform for Enrichment, Detection, and Enumeration of Circulating Tumor Cells (CTCs): Potential Application as a Liquid Biopsy for Development of Companion Diagnostic TestsSELECTBIOenquiries@selectbiosciences.com
